Show simple item record

dc.contributor.authorSt Peter, Wendy L
dc.contributor.authorSozio, Stephen M
dc.contributor.authorShafi, Tariq
dc.contributor.authorEphraim, Patti L
dc.contributor.authorLuly, Jason
dc.contributor.authorMcDermott, Aidan
dc.contributor.authorBandeen-Roche, Karen
dc.contributor.authorMeyer, Klemens B
dc.contributor.authorCrews, Deidra C
dc.contributor.authorScialla, Julia J
dc.contributor.authorMiskulin, Dana C
dc.contributor.authorTangri, Navdeep
dc.contributor.authorJaar, Bernard G
dc.contributor.authorMichels, Wieneke M
dc.contributor.authorWu, Albert W
dc.contributor.authorBoulware, L E
dc.contributor.authorthe DEcIDE Network Patient Outcomes in End-Stage Renal Disease Study Investigators
dc.date.accessioned2013-11-23T00:05:36Z
dc.date.available2013-11-23T00:05:36Z
dc.date.issued2013-11-12
dc.identifier.citationBMC Nephrology. 2013 Nov 12;14(1):249
dc.identifier.urihttp://hdl.handle.net/1993/22270
dc.description.abstractAbstract Background Several observational studies have evaluated the effect of a single exposure window with blood pressure (BP) medications on outcomes in incident dialysis patients, but whether BP medication prescription patterns remain stable or a single exposure window design is adequate to evaluate effect on outcomes is unclear. Methods We described patterns of BP medication prescription over 6 months after dialysis initiation in hemodialysis and peritoneal dialysis patients, stratified by cardiovascular comorbidity, diabetes, and other patient characteristics. The cohort included 13,072 adult patients (12,159 hemodialysis, 913 peritoneal dialysis) who initiated dialysis in Dialysis Clinic, Inc., facilities January 1, 2003-June 30, 2008, and remained on the original modality for at least 6 months. We evaluated monthly patterns in BP medication prescription over 6 months and at 12 and 24 months after initiation. Results Prescription patterns varied by dialysis modality over the first 6 months; substantial proportions of patients with prescriptions for beta-blockers, renin angiotensin system agents, and dihydropyridine calcium channel blockers in month 6 no longer had prescriptions for these medications by month 24. Prescription of specific medication classes varied by comorbidity, race/ethnicity, and age, but little by sex. The mean number of medications was 2.5 at month 6 in hemodialysis and peritoneal dialysis cohorts. Conclusions This study evaluates BP medication patterns in both hemodialysis and peritoneal dialysis patients over the first 6 months of dialysis. Our findings highlight the challenges of assessing comparative effectiveness of a single BP medication class in dialysis patients. Longitudinal designs should be used to account for changes in BP medication management over time, and designs that incorporate common combinations should be considered.
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titlePatterns in blood pressure medication use in US incident dialysis patients over the first 6 months
dc.typeJournal Article
dc.typeinfo:eu-repo/semantics/article
dc.language.rfc3066en
dc.description.versionPeer Reviewed
dc.rights.holderWendy L St Peter et al.; licensee BioMed Central Ltd.
dc.date.updated2013-11-23T00:05:37Z
dc.identifier.doihttp://dx.doi.org/10.1186/1471-2369-14-249


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record